Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026)
Avalo Therapeutics' (AVTX) quarterly Deferred Taxes came in at $12000.0 in Q1 2026, up 50.0% YoY from $8000.0 in Q1 2025, and down 90.84% on a QoQ basis from $131000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of Deferred Taxes data on file, last reported at $12000.0 in Q1 2026.
- Quarterly Deferred Taxes rose 50.0% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169000.0 (up 46.96% YoY) and the FY2025 annual result came in at $165000.0, up 44.74% from the prior year.
- Deferred Taxes retreated to $12000.0 in Q1 2026, from $131000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $131000.0 in Q4 2025 to a low of -$14000.0 in Q3 2024.
- A 5-year average of $19588.2 and a median of $8000.0 in 2022 frame the typical range for Deferred Taxes.
- The widest YoY moves for Deferred Taxes: up 1366.67% in 2024, down 275.0% in 2024.
- Tracing AVTX's Deferred Taxes over 5 years: stood at $8000.0 in 2022, then tumbled by 212.5% to -$9000.0 in 2023, then soared by 1366.67% to $114000.0 in 2024, then rose by 14.91% to $131000.0 in 2025, then tumbled by 90.84% to $12000.0 in 2026.
- The last three Deferred Taxes figures came in at $12000.0 (Q1 2026), $131000.0 (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 9,000.00 |